These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35280756)

  • 1. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
    Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
    Front Oncol; 2022; 12():804466. PubMed ID: 35280756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
    J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
    Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
    Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
    Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
    Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of Programmed Death Receptor Ligand 1 Expression and Clinicopathological Factors Associated With Metastatic Triple-Negative Breast Cancer at a Tertiary Cancer Care Centre in South India.
    Babu S; Choudhary A; Jacob L; K N L; A H R; L K R; Saldanha S; Amirtham U; C R V
    Cureus; 2024 Mar; 16(3):e55880. PubMed ID: 38595897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.
    Huang X; Xie X; Wang H; Xiao X; Yang L; Tian Z; Guo X; Zhang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 Sep; 36(1):129. PubMed ID: 28915924
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of CD117 expression and
    Luo Y; Huang W; Zhang H; Liu G
    Oncol Lett; 2018 May; 15(5):6161-6170. PubMed ID: 29616097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
    Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting.
    Wu Z; Zhang L; Peng J; Xu S; Zhou L; Lin Y; Wang Y; Lu J; Yin W; Lu J
    Cancer Biol Ther; 2019; 20(6):941-947. PubMed ID: 30866717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer.
    Tang Y; Zhu L; Li Y; Ji J; Li J; Yuan F; Wang D; Chen W; Huang O; Chen X; Wu J; Shen K; Loo WT; Chow LW
    J Transl Med; 2012 Sep; 10 Suppl 1(Suppl 1):S4. PubMed ID: 23046633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer.
    Katsuta E; Yan L; Opyrchal M; Kalinski P; Takabe K
    Ther Adv Med Oncol; 2021; 13():17588359211006680. PubMed ID: 33868461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression.
    Boudin L; De Nonneville A; Finetti P; Guittard G; Nunes JA; Birnbaum D; Mamessier E; Bertucci F
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
    Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
    Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC).
    Ghosh J; Chatterjee M; Ganguly S; Datta A; Biswas B; Mukherjee G; Agarwal S; Ahmed R; Chatterjee S; Dabkara D
    Ecancermedicalscience; 2021; 15():1217. PubMed ID: 34158821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.